Scout Bio is a privately held biotechnology company revolutionizing pet medicine by delivering a pipeline of one-time gene therapies for major chronic pet health conditions. Scout Bio’s therapies are designed to induce long-term expression of therapeutic proteins in pet patients after a single injection. The novel single injection adeno-associated virus (AAV) vector treatments intend to improve treatment compliance, treatment outcomes, and the quality of life for companion animals by eliminating the need for daily or monthly administration.  Therapeutic products target a number of major chronic diseases and markets, including diabetes, osteoarthritic pain, atopic dermatitis, and feline anemia associated with chronic kidney disease. Headquartered in Philadelphia, Pennsylvania, Scout Bio has a research and development collaboration with the University of Pennsylvania’s Gene Therapy Program, a leader in the field of genetic medicine research.